These findings suggest that when a breast cancer patient is being administered PTX as a therapy, the cancer cells within a tumor will begin to generate increased amounts of exosomes, as well as increase the levels of Survivin in these vesicles. This evidence concerns the gene BIRC5 and neoplasm.